Inspire(ISPH Quote) jumped 3% after announcing late Friday that the Food and Drug Administration approved AzaSite 1% for treatment of bacterial conjunctivitis. It expects to launch the drug in the third quarter, and predicts $30 million to $45 million in U.S. sales. The stock rose 21 cents to $7.59.
Regenerative medicine company Aastrom Biosciences (ASTM Quote) announced on Monday that it has initiated its U.S. Phase IIb clinical trial to treat critical limb ischemia in patients suffering from peripheral arterial disease. Shares were up 3 cents, or 2.1%, to $1.44 on Monday.
Pharmaceutical company Sanofi-Aventis(SNY Quote) saw shares sink 19 cents, or 0.4%, to $46.06, even though the company announced the FDA approved hyperglycemeia treatment Solostar. The disposable insulin pen for helping treat hyperglycemeia in Type 1 or 2 diabetes patients is expected to be available in U.S. pharmacies later this year. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet